Corporate Profile

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions.

We believe EG-1962, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. Read More

Stock Information

EDGE (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$10.71
Change (%) Stock is Up 0.15 (1.42%)
Volume16,013
Data as of August 18, 2017 4:00 p.m. ET
Refresh quote

IR Contact

Gregory Gin
Email: ir@edgetherapeutics.com

Upcoming Events

There are currently no events scheduled.
More >>

Presentation

DateTitle
June 6, 2017
Download Documentation Investor Presentation – June 2017

Lastest News

August 1, 2017 - Edge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational Progress
Read More
July 18, 2017 - Edge Therapeutics Announces Second Quarter Financial Results Conference Call on August 1, 2017
Read More
July 6, 2017 - Edge Therapeutics Announces Commercial Supply Agreement for EG-1962 with Oakwood Laboratories
Read More

More >>

Data provided by Nasdaq. Minimum 15 minutes delayed.

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts